Why the study?
Does diallyl trisulfide reduce myocardial ischemia-reperfusion injury in diabetic models?
Does diallyl trisulfide reduce myocardial ischemia-reperfusion injury in diabetic models?
Diallyl trisulfide protects against myocardial ischemia-reperfusion injury in diabetic models by attenuating cellular apoptosis via AMPK-mediated AKT/GSK-3β/HIF-1α signaling.
Answers are grounded in this paper and cite their sources.
May support diallyl trisulfide optimization in diabetic models; leaves open human translation for myocardial ischemia-reperfusion.
// Liming Yu 1, * , Wencheng Di 2, * , Xue Dong 3, 4, * , Zhi Li 1 , Xiaodong Xue 1 , Jian Zhang 1 , Qi Wang 1, 5 , Xiong Xiao 1, 6 , Jinsong Han 1 , Yang Yang 7, 8 and Huishan Wang 1 1 Department of Cardiovascular Surgery, General Hospital of Shenyang Military Area Command, Shenyang, Liaoning 110016, China 2 Department of Cardiology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China 3 Department of Pharmacy, General Hospital of Shenyang Military Area Command, Shenyang, Liaoning 110016, China 4 Department of Neurosurgery, General Hospital of Shenyang Military Area Command, Shenyang, Liaoning 110016, China 5 Graduate School, Dalian Medical University, Dalian, Liaoning 116044, China 6 Department of Cardiovascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China 7 Faculty of Life Science, Northwest University, Xi’an, Shaanxi 710069, China 8 Department of Biomedical Engineering, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China * These authors have contributed equally to this work Correspondence to: Huishan Wang, email: huishanw@126.com Yang Yang, email: yang200214yy@163.com Keywords: diallyl trisulfide, diabetes mellitus, myocardial ischemia-reperfusion injury, AMPK, AKT/GSK-3β/HIF-1α signaling Received: April 11, 2017 Accepted: June 28, 2017 Published: August 24, 2017 ABSTRACT Diallyl trisulfide (DATS), the major active ingredient in garlic, has been reported to confer cardioprotective effects. However, its effect on myocardial ischemia-reperfusion (MI/R) injury in diabetic state and the underlying mechanism are still unknown. We hypothesize that DATS reduces MI/R injury in diabetic state via AMPK-mediated AKT/GSK-3β/HIF-1α activation. Streptozotocin-induced diabetic rats received MI/R surgery with or without DATS (20mg/kg) treatment in the presence or absence of Compound C (Com.C, an AMPK inhibitor, 0.25mg/kg) or LY294002 (a PI3K inhibitor, 5mg/kg). We found that DATS significantly improved heart function and reduced myocardial apoptosis. Additionally, in cultured H9c2 cells, DATS (10μM) also attenuated simulated ischemia-reperfusion injury. We found that AMPK and AKT/GSK-3β/HIF-1α signaling were down-regulated under diabetic condition, while DATS markedly increased the phosphorylation of AMPK, ACC, AKT and GSK-3β as well as HIF-1α expression in MI/R-injured myocardium. However, these protective actions were all blunted by Com.C administration. Additionally, LY294002 abolished the stimulatory effect of DATS on AKT/GSK-3β/HIF-1α signaling without affecting AMPK signaling. While 2-methoxyestradiol (a HIF-1α inhibitor) reduced HIF-1α expression without affecting AKT/GSK-3β signaling. Taken together, these data showed that DATS protected against MI/R injury in diabetic state by attenuating cellular apoptosis via AMPK-mediated AKT/GSK-3β/HIF-1α signaling. Its cardioprotective effect deserves further study.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: